<DOC>
	<DOCNO>NCT01403038</DOCNO>
	<brief_summary>This open-label Phase 1 study healthy premenopausal female evaluate effect different dose regimen elagolix ovarian activity , ovulation , ovarian reserve ass effect elagolix select endocrine/hormone level .</brief_summary>
	<brief_title>An Open-label Study Effects Elagolix Adult Premenopausal Females</brief_title>
	<detailed_description>This open-label , multiple-dose , Phase 1 study premenopausal subject age 18 year 40 year , history regular menstrual cycle ( 24 32 day long ) evidence significant gynecological disorder . The objective study determine effect different dose regimen elagolix ovulation , ovarian activity , ovarian reserve . The study consist 3 period : Screening Period 50 day prior first dose , Treatment Period 3 month duration ( Cycles 1-3 ) , Follow-up Period 60 day . During Screening Treatment menstrual cycle , serial transvaginal ultrasound determination serum level luteinizing hormone , follicle-stimulating hormone , estradiol , progesterone , inhibin B perform three time weekly . Subjects maintain daily diary uterine bleeding . Pregnancy test perform frequently throughout study . Subjects require use nonhormonal dual contraception consistently study , counsel appropriate effective form birth control promote pregnancy prevention .</detailed_description>
	<criteria>Premenopausal female , 18 40 year age , inclusive History regular menstrual cycle Endocrine ultrasonographic evidence ovulation normal ovulatory cycle screen period Folliclestimulating hormone level &lt; 35 mIU/mL Agrees use require birth control method entire length participation study Screening ultrasound result show clinically significant gynecological disorder Surgical history hysterectomy without oophorectomy , unilateral bilateral oophorectomy , removal ovarian cysts Less 6 month postpartum postlactation start study drug dose Pregnant breast feed planning pregnancy within next 12 month Testosterone concentration &gt; 120 ng/dL screen</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>healthy volunteer</keyword>
	<keyword>elagolix</keyword>
	<keyword>endometriosis</keyword>
	<keyword>ovarian reserve</keyword>
	<keyword>gonadotropin-releasing hormone antagonist</keyword>
	<keyword>ovulation</keyword>
	<keyword>ovarian activity</keyword>
</DOC>